STOCK TITAN
  1. Home
  2. Sec-filings
  3. BIO
  4. [Form 4] Bio-Rad Laboratories, Inc. Insider Trading Activity

Bio-Rad Laboratories (NYSE: BIO) EVP Colleen Corey vests 1,102 shares, with 398 withheld for taxes

Filing Impact
(Moderate)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Bio-Rad Laboratories EVP Colleen Corey reported RSU vesting on September 1, 2025. Three tranches of restricted stock units (254, 347 and 501) converted into 1,102 shares of Bio-Rad Class A common stock. To satisfy tax obligations, 398 shares were withheld at $297.88 per share. After these transactions, she directly holds 19,183 shares of Class A common stock and 1,349 restricted stock units.

Positive

  • None.

Negative

  • None.

Insights

TL;DR: Routine executive equity vesting and a partial sale; transactions reflect compensation vesting and a small sale at $297.88 per share.

This Form 4 documents standard compensation-related activity: the vesting of restricted stock units resulting in 1,102 shares issued and a separate sale of 398 shares at $297.88 each. The post-transaction beneficial ownership levels are disclosed, and the explanatory notes tie the RSUs to grants made in 2021-2023 with four-year vesting schedules. For investors, this is a routine insider disclosure with no new operational or financial information about Bio-Rad's business performance.

TL;DR: Standard compliance filing showing award vesting and a reported disposition; documentation and vesting schedules are clearly disclosed.

The Form 4 includes clear attribution of the acquired shares to RSU vesting and identifies the reporting person as EVP, Global Human Resources. The form lists grant years (2021, 2022, 2023) and specifies vesting in four equal annual installments beginning on each grant's first anniversary. Signatures and dates are provided, indicating timely filing. This is a routine disclosure consistent with Section 16 reporting requirements.

Insider COREY COLLEEN
Role EVP, Global Human Resources
Type Security Shares Price Value
Exercise Restricted Stock Units 254 $0.00 $0.00
Exercise Restricted Stock Units 347 $0.00 $0.00
Exercise Restricted Stock Units 501 $0.00 $0.00
Exercise Bio-Rad A Common Stock 1,102 $0.00 $0.00
Exercise Price or Tax Liability Bio-Rad A Common Stock 398 $297.88 $119K
Holdings After Transaction: Restricted Stock Units — 1,349 shares (Direct); Bio-Rad A Common Stock — 19,183 shares (Direct)
Footnotes (5)
  1. F1. Shares of Class A common stock acquired on the vesting of restricted stock units.
  2. F2. Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock.
  3. F3. On September 1, 2021, the reporting person was granted 1,013 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date.
  4. F4. On September 1, 2022, the reporting person was granted 1,388 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date.
  5. F5. On September 1, 2023, the reporting person was granted 2,003 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date.
RSUs converted 254 restricted stock units Restricted stock units converting into Bio-Rad Class A common stock on September 1, 2025
RSUs converted 347 restricted stock units Additional RSUs converting into Bio-Rad Class A common stock on September 1, 2025
RSUs converted 501 restricted stock units Third RSU tranche converting into Bio-Rad Class A common stock on September 1, 2025
Shares acquired via RSU vesting 1,102 shares Bio-Rad Class A common stock received upon exercise/conversion of RSUs on September 1, 2025
Tax-withheld shares 398 shares Bio-Rad Class A common stock withheld to satisfy tax obligations on September 1, 2025
Tax-withholding price $297.88 per share Per-share value used for tax-withholding disposition of 398 shares
Post-transaction common stock holding 19,183 shares Direct Bio-Rad Class A common stock held by Colleen Corey after reported transactions
Post-transaction RSU holding 1,349 restricted stock units Direct RSU balance reported after the September 1, 2025 vesting events
Restricted Stock Units financial
"Three tranches of restricted stock units (254, 347 and 501) converted"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
Class A common stock financial
"converted into 1,102 shares of Bio-Rad Class A common stock"
Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.
tax-withholding disposition financial
"classified as a tax-withholding disposition rather than an open-market sale"
A tax-withholding disposition is an event or transaction—such as selling or transferring securities, exercising options, or receiving compensation—that triggers a requirement to hold back part of the payment and remit it to tax authorities. It matters to investors because it reduces the cash they receive immediately and can change the timing and amount of taxable income, like a cashier taking a portion of your sale proceeds to pay taxes before you get the rest.
contingent right financial
"Each restricted stock unit represents a contingent right to receive one share"
annual installments financial
"vesting in four equal annual installments beginning on the first anniversary"

FAQ

What did Bio (BIO) EVP Colleen Corey report in this Form 4?
EVP Colleen Corey reported vesting of restricted stock units that converted into 1,102 Bio-Rad Class A shares, with a portion withheld for taxes, and disclosed her updated direct holdings in common stock and RSUs.

How many Bio-Rad (BIO) shares did Colleen Corey receive from RSU vesting?
Colleen Corey received 1,102 shares of Bio-Rad Class A common stock upon the exercise/vesting of restricted stock units, coming from three tranches of 254, 347 and 501 RSUs that each represent one share of Class A common stock.

How many Bio (BIO) shares were withheld for Colleen Corey’s taxes?
To cover tax obligations, 398 shares of Bio-Rad Class A common stock were withheld at a per-share price of $297.88, classified as a tax-withholding disposition rather than an open-market sale transaction.

What are Colleen Corey’s Bio-Rad (BIO) holdings after these transactions?
Following the September 1, 2025 transactions, Colleen Corey directly holds 19,183 shares of Bio-Rad Class A common stock and 1,349 restricted stock units, reflecting her updated equity position in the company after RSU vesting and tax withholding.

What RSU grant schedules are disclosed for Bio (BIO) EVP Colleen Corey?
Corey was granted 1,013 RSUs in 2021, 1,388 RSUs in 2022, and 2,003 RSUs in 2023, each vesting in four equal annual installments beginning on the first anniversary of the respective grant date, subject to standard RSU terms.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
COREY COLLEEN
(Last) (First) (Middle)
C/O BIO-RAD LABORATORIES, INC.
1000 ALFRED NOBEL DRIVE
(Street)
HERCULES CA 94547
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
BIO-RAD LABORATORIES, INC. [ BIO BIO.B ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
EVP, Global Human Resources
3. Date of Earliest Transaction (Month/Day/Year)
09/01/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Bio-Rad A Common Stock 09/01/2025 M 1,102(1) A $0 19,581 D
Bio-Rad A Common Stock 09/01/2025 F 398 D $297.88 19,183 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Units $0(2) 09/01/2025 M 254 (3) (3) Bio-Rad A Common Stock 254 $0 0 D
Restricted Stock Units $0(2) 09/01/2025 M 347 (4) (4) Bio-Rad A Common Stock 347 $0 347 D
Restricted Stock Units $0(2) 09/01/2025 M 501 (5) (5) Bio-Rad A Common Stock 501 $0 1,002 D
Explanation of Responses:
1. Shares of Class A common stock acquired on the vesting of restricted stock units.
2. Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock.
3. On September 1, 2021, the reporting person was granted 1,013 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date.
4. On September 1, 2022, the reporting person was granted 1,388 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date.
5. On September 1, 2023, the reporting person was granted 2,003 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date.
Remarks:
/s/ Colleen Corey 09/02/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR